

**CORRECTED
VERSION***

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00, 45/05, 38/19, 39/395	A1	(11) International Publication Number: WO 97/46249 (43) International Publication Date: 11 December 1997 (11.12.97)
(21) International Application Number: PCT/US97/09684		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 4 June 1997 (04.06.97)		
(30) Priority Data: 60/018,972 4 June 1996 (04.06.96) US		
(71) Applicant (<i>for all designated States except US</i>): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10666 North Torrey Pines Road, Mail Drop TPC-8, La Jolla, CA 92037 (US).		
(72) Inventors; and		Published
(75) Inventors/Applicants (<i>for US only</i>): FENG, Lili [CN/US]; 7430 Mason Heights Lane, San Diego, CA 92126 (US). CHEN, Sizhong [CN/US]; 7896 Camino Kiosco, San Diego, CA 92122 (US). XIA, Yiyang [CN/US]; 7430 Mason Heights Lane, San Diego, CA 92126 (US).		<i>With international search report.</i>
(74) Agents: OLSON, Arne, M.; Olson & Hierl, Ltd., 36th floor, 20 North Wacker Drive, Chicago, IL 60606 (US) et al.		

(54) Title: DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO REGULATING ENERGY MOBILIZATION WITH OB PROTEIN AND OB ANTIBODIES

(57) Abstract

Compositions comprising OB-R agonists and methods of treatment for conditions such as systemic inflammatory response syndrome are provided. One suitable OB-R agonist ligand is recombinant human OB protein, also known as leptin. Also provided are methods and compositions for the treatment of obesity and OB resistance. Assay methods and kits relating to these conditions are also included.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO
REGULATING ENERGY MOBILIZATION WITH
OB PROTEIN AND OB ANTIBODIES**

5 **Reference to Related Application**

This application claims the benefit of U.S. Provisional Application S.N. 60/018,972, filed June 4, 1996, which is incorporated by reference, as are all references cited herein.

Governmental Rights

10 This invention was made with governmental support from the United States Government, National Institutes of Health, Grant DK20043; the United States Government has certain rights in the invention.

Background of the Invention

15 The *obese* gene in human, rat and mouse encodes a protein hormone having an open reading frame 167 amino acid residues in length, called leptin, also known as OB protein or the *ob* gene product. Removal of the signal sequence yields a mature secreted 16 kilodalton protein that is 146 amino acid residues in length.

20 OB protein is produced primarily by adipocytes of white adipose tissue (WAT). OB protein is secreted directly into the extracellular space and travels through the blood stream. OB protein affects the cells of its target organs by binding to the OB receptor protein, OB-R, that is found on the extracellular surface of the plasma membrane of target cells. Binding of OB protein to OB-R activates the intracellular second messenger cascade of the JAK-STAT system,
25 which is characteristic of activation of cytokine type I receptors.

OB protein is produced in adipocytes in proportion to the mass of stored fat, thereby providing a hormone signal for a lipostatic feedback circuit, which is mediated by the OB receptor. While OB proteins of different species show a close similarity in their sequences, the sequences of OB proteins are not closely similar to other types of proteins. For example, the human *ob* gene
30

sequence and its mouse homologue (85% sequence identity) have been reported to have no sequence similarity to other proteins of known structure (DiFrancesco, V., et al., Protein Topology Recognition from Secondary Structure Sequences: Application of the Hidden Markov Models to Alpha Class Proteins, J. Mol. Biol. 5 **267**: 446-463 (1997) at page 457).

Although OB protein is composed of a single peptide chain, an intrachain disulfide bond between cysteine 96 and cysteine 146 is required both to stabilize the conformation of the molecule and to confer in vivo biological activity (Rock, F.L., et al., The Leptin Haemopoietic Cytokine Fold is Stabilized by an 10 Intrachain Disulfide Bond, Horm. Metab. Res. **28**: 649-652 (1996)). It is believed that the special geometry of the A and D major helices must be maintained in order to dock to a conserved receptor trough in the receptor molecule, a requirement that produces structural similarity between OB proteins and cytokines in the face of negligible sequence conservation (Id. at 651.).

One accepted and successful animal model of human obesity is the genetically obese mouse bearing the recessive *obese* mutation (*ob/ob*). The mouse model reproduces not only the human obesity condition, but also develops non-insulin dependent diabetes mellitus (NIDDM, also known as type II diabetes mellitus). Homologous *obese* genes have been described in mouse, rat and 20 human.

The mouse is also a widely accepted and successful model of sepsis, septic shock and systemic inflammatory response syndrome (SIRS), a term which describes the clinical syndrome of sepsis without regard to its cause. Simple models, involving a large bolus dose of lipopolysaccharide (LPS) 25 administered to mice and using mortality as the primary outcome variable, are well suited for preliminary pharmacological studies of new drugs or other therapeutic agents (Fink, M.P. & Heard, S.O., Laboratory Models of Sepsis and Septic Shock, J. Surg. Res. **49**: 186-196, 1990, at 188-189).

Both the *ob* gene (Zhang, Y., et al., Positional cloning of the 30 mouse *obese* gene and its human homologue, Nature **372**: 425-432 (1994);

accession No. U18812, SEQ ID NO. 1) and its receptor (Tartaglia, L.A., et al., Identification and expression cloning of a Leptin Receptor, Cell 83: 1263-1271 (1995); Chen, H., et al., Evidence that the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in *db/db* Mice Cell 84: 491-495 (1996); accession No. U46135, SEQ ID NO. 2) have been cloned. Shorter versions of the OB receptor, termed the OB-Ra, OB-Rc and OB-Re forms, are produced by alternative splicing of the OB-R mRNA (Lee, G.-H., et al. Nature 379: 632-635 (1996)). The full length OB receptor is called the OB-Rb form.

10 Neural activity in specific regions of the central nervous system (CNS), such as the hypothalamus, controls processes related to food intake and energy expenditure. The cloning of the OB protein gene and the OB receptor gene and the localization of OB receptor expression in the hypothalamus has provided supporting evidence for this view as well as suggesting possible mechanisms for relating food intake to stored fat reserves. The OB protein is produced by adipocytes in proportion to the mass of stored fat and, hence, it acts as the signal to a lipostat control circuit. This lipostat signal is transduced at the target cells by the OB receptor, OB-R, in the CNS, resulting changes in neural activity that regulate both food intake and metabolic rate.

15 Metabolic derangement is an important characteristic of the host response to critical illness called the acute phase response that characterizes conditions such as sepsis and septic shock (Kushner, I. Ann. N.Y. Acad. Sci. 389: 39-48 (1982)). Hypothermia is a metabolic response that may be pertinent clinical prognostic factor in systemic inflammatory response syndrome in humans (Brivet, F., et al. Crit. Care Med. 22: 533-534 (1994)).

20 There is a need for at least one disease marker for systemic inflammatory response syndrome (SIRS) and related conditions. Hereinafter, the term SIRS is used to denote sepsis, septic shock, sepsis syndrome, and related conditions. Disease markers have numerous functions. In this case, a marker for SIRS would be useful for predicting the development of SIRS, identifying patients

with SIRS, predicting outcome, aiding timing and targeting of therapeutic interventions, and determining the pathogenesis of SIRS in patients (Parsons, P.E. & Moss, M. Early Detection and Markers of Sepsis, Clinics in Chest Medicine 17:199-212 (1996)).

5 Summary of the Invention

Embodiments of the present invention include compositions and methods for treating a patient having a condition in which regulating energy metabolism during a systemic inflammatory response is desired, comprising administering a composition having a physiologically effective amount of at least 10 one OB-R agonist ligand. Suitable OB-R agonist ligands include recombinant OB protein, peptide conformational analogs of human OB protein comprising conservative substitutions of amino acid residues and OB-related peptides. A preferred OB-R agonist ligand is recombinant human OB protein.

In another therapeutic embodiment, the beneficial aspects of OB-R 15 agonist ligand administration are facilitated by a coordinated increase in the number of OB receptors (OB-R) produced by the administration of agents that OB-R expression inducers. Suitable OB-R expression inducers include lipopolysaccharide (LPS) and cytokines. Preferred cytokines are interleukin-1 α (IL-1 α), interleukin-1 β (IL-1 β), tumor necrosis factor- α (TNF- α) and interleukin 20 6 (IL-6). Particularly preferred cytokines are IL-6 and IL-1 β .

In a further therapeutic embodiment, antibodies to OB protein are used as agents capable of blocking the effects of OB receptor activation, especially fat mobilization and increased energy utilization. Suitable antibodies to OB proteins may be polyclonal or monoclonal. Suitable antibodies comprise 25 immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope. Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab' and F(ab')₂. This embodiment is suitable for 30

treating metabolic derangement due to conditions such as anorexia, amenorrhea, cachexia and the like.

Antibodies to OB protein are also useful as an assay kit and method for detecting the level of OB protein in a patient. The level of OB protein in a patient is a disease marker that is useful for predicting the development of a condition, identifying patients with the condition, predicting outcome of the condition, aiding timing and targeting of therapeutic interventions, and determining the pathogenesis of the condition in patients. Conditions in which the level of OB protein is a useful marker are SIRS and related conditions such as sepsis and septic shock, as well as anorexia, amenorrhea, cachexia and the like.

Brief Summary of the Drawings

In the drawings:

Figure 1 is a representation of an autoradiogram showing the results of a ribonuclease (RNase) protection assay showing expression of total OB receptor (OB-R_(t)) in lung, kidney and liver at 0, 4, 8 or 24 hours, or 2 (D₂), 3 (D₃) or 5 (D₅) days after intravenous injection of 5 µg per gram of body weight as well as a dose-response study showing the relative effects on the liver of injection of 0.05, 0.5 or 5 µg of LPS per gram of body weight;

Figure 2 is a representation of an autoradiogram showing of the results of a RNase protection assay showing expression of OB-Rb in normal liver (lane 1), and the LPS-treated liver at 24 hours (lane 2), and in the hypothalamus of normal control (lane 3) and *ob/ob* mice (lane 4), compared to OB-R_(m) which represents the mixture of OB-R forms partially protected by the designated nucleotide probes;

Figure 3 is a representation of an autoradiogram showing the results of a RNase protection assay showing expression of OB-Rc in normal liver (lane 1), and the LPS-treated liver at 24 hours (lane 2), and in the hypothalamus of normal control (lane 3) and *ob/ob* mice (lane 4), compared to OB-R_(m) which

represents the mixture of OB-R forms partially protected by the designated nucleotide probes;

Figure 4 is a representation of an autoradiogram showing the results of a RNase protection assay showing expression of OB-Re in normal liver (lane 1), and the LPS-treated liver at 24 hours (lane 2), and in the hypothalamus of normal control (lane 3) and *ob/ob* mice (lane 4), compared to OB-R_(m) which represents the mixture of OB-R forms partially protected by the designated nucleotide probes;

Figure 5 is a representation of an autoradiogram showing the results of a RNase protection assay showing OB-R expression in mouse liver 24 hours after IL-6 (2.5 µg per mouse), TNF- α (10 µg per mouse) and IL-1 β (5 µg per mouse) injection;

Figure 6 is a representation of an autoradiogram showing the results of a RNase protection assay showing OB-R mRNA levels in brain cortex, hypothalamus, and brain stem at various times after LPS injection (5 µg per gram of body weight);

Figure 7 is a representation of an autoradiogram showing the results of a RNase protection assay showing OB mRNA expression in the adrenal gland (Adr) and white adipose tissue (WAT) at various times after LPS injection (5 µg per gram of body weight);

Figure 8 is a graphical representation of the construction scheme for the vector pETM1 from a commercially available vector;

Figure 9 is a graphical representation of the weight gain induced by anti-OB antiserum injection in C57BL/6 mice which were given daily injections of anti-OB antiserum (antiOB) or preimmune rabbit sera (control), and whose body weight was measured 12 hours later, where data are expressed as mean \pm standard error of the mean (S.E.M), N=8;

Figure 10 is a graphical representation of the time course of the survival of mice that had received a LPS injection (6 µg per gram of body weight) after pretreatment with either anti-OB protein antiserum (anti-OB,

N=16), preimmune rabbit serum (control, N=16), or one of three other unrelated rabbit antisera (anti-X, N=9: 3 treated with each antiserum);

Figure 11 is a graphical representation of the time course of the survival of mice that were treated with OB protein (mOB, N=16) or vehicle (control, N=16) after a LPS injection (10 μ g per gram of body weight);

Figure 12 is a graphical representation of the time course of the change in body temperature of mice that had received a LPS injection (6 μ g per gram of body weight) after pretreatment with either anti-OB protein antiserum (anti-OB, N=16, except at * where N<16 due to mortality) or preimmune rabbit serum (control, N=16), data expressed as mean \pm S.E.M.;

Figure 13 is a graphical representation of the time course of the change in body temperature of mice that were treated with OB protein (mOB, N=16) or vehicle (control, N=16, except at * where N<16 due to mortality) after a LPS injection (10 μ g per gram of body weight), data expressed as mean \pm S.E.M.;

Figure 14 is a graphical representation of the time course of the change in body weight (percent of initial body weight) of mice that had received a LPS injection (6 μ g per gram of body weight) after pretreatment with either anti-OB protein antiserum (anti-OB, N=16) or preimmune rabbit serum (control, N=16, except at * where N<16 due to mortality), data expressed as mean \pm S.E.M.;

Figure 15 is a graphical representation of the time course of the change in body weight (percent of initial body weight) of mice that were treated with OB protein (mOB, N=16) or vehicle (control, N=16, except at * where N<16 due to mortality) after a LPS injection (10 μ g per gram of body weight), data expressed as mean \pm S.E.M.; and

Figure 16 is a representation of an autoradiogram showing the results of a RNase protection assay showing the expression of iNOS, IL-1 α , IL-1 β , and TNF- α mRNAs in mouse.

Detailed Description of the Preferred Embodiments

It has been found that substances that initiate or mediate SIRS, for example, LPS and several cytokines, induce the increased expression of OB-R in liver and other peripheral tissues. Thus, occupancy and activation of OB-R by an agonist ligand such as recombinant OB protein, OB-related peptides or peptide conformational analog of human OB protein comprising conservative substitutions of amino acid residues serves as a protective homeostatic mechanism in systemic inflammatory response syndrome conditions such as endotoxic shock, sepsis and septic shock. A preferred OB-R agonist ligand is recombinant OB protein.

Suitable therapeutic human doses of recombinant OB protein are from about 1 micrograms per kilogram body weight to about 50 microgram per kilogram body weight. One preferable therapeutic human dose is about 10 micrograms per kilogram body weight.

While the regulation of energy homeostasis is essentially a function of the CNS, food intake and the majority of the energy expenditure take place in peripheral organs such as the liver. It has been found that the OB protein and the OB receptor have a functional involvement in peripheral energy homeostasis. In general, critical illness and trauma can dramatically alter metabolism, with the expression of the OB receptor changing in response to pathological stress. The expression of OB-R in liver and other peripheral organs, but not in the central nervous system, has now been shown to be induced by endotoxic shock produced intravenous injection of cytokines, such as, IL-1 β , TNF- α and IL-6, as well as cytokine inducing agents such as LPS, into mice, an accepted animal model of SIRS and related conditions. OB protein, antibodies to OB protein, and OB-R expression inducers are useful for the diagnosis and treatment of conditions such as sepsis, systemic inflammatory response syndrome, cachexia and anorexia.

The administration of recombinant mouse OB protein to mice following OB-R induction with a normally lethal dose of LPS conferred complete resistance to LPS, resulting in survival. The OB-treated mice maintained a higher body temperature and displayed dramatic weight loss in contrast to control

counterparts. In vivo administration of OB antisera, on the other hand, elicited the opposite effects by blocking OB-mediated processes, thereby stimulating post-prandial food intake leading to rapid weight gain. Co-administration of LPS with a second in vivo treatment with OB antisera, however, resulted in 100% mortality as compared to animals treated with control antisera.

OB protein, in mediating host responses to LPS-induced endotoxemia, exerts its protective effect primarily by initiating energy mobilization and heat production in critical conditions, the effect of which is proportional to the level of OB protein in the blood. By altering the levels of OB protein, the amount of energy mobilized to resist challenges induced by inflammatory agents is correspondingly altered, thereby effecting the ultimate inflammatory response.

Therefore, in view of the newly discovered physiological properties of OB protein and OB antibodies in regulating energy mobilization and consumption, the present invention describes both diagnostic and therapeutic methods relating to the use of recombinant human OB protein and antibodies thereto in modulating the effects of OB-R activation in vivo.

Diagnostic Applications

OB antibodies are useful for detecting the amount of OB present in sample taken from a patient. One preferred diagnostic embodiment is the use of OB antibodies for detecting the amount of OB present in a blood sample taken from a patient exhibiting a SIRS condition such as sepsis, septic shock, and the like. Such measurements of OB levels in vitro in blood sample by antibody detection is also indicated in various wasting conditions or syndromes associated with several disease states or syndromes, including anorexia, amenorrhea, cachexia, chronic inflammatory conditions, AIDS and AIDS-related conditions, as well as sepsis, septic shock, SIRS and the like. Alternatively, the determination of OB levels is useful in systemic inflammatory response syndromes (SIRS) that are characterized by an acute increase in inflammatory mediators, such as IL-1 β , IL-6, TNF, LPS and the like. Such conditions are noted in preoperative patients

subject to fasting, in patients with acute injuries such as burns or trauma, in patients with SIRS, or with ongoing bacterial infections or those receiving TNF- α for treatment of tumors and in persons suffering from hypothermia.

While there is little sequence similarity between OB proteins and other molecules, the three-dimensional conformation of the OB protein molecule is analogous to that of several long-chain helical cytokines: four major alpha helix regions, A-D, connected by short loops and minor helical regions (Zhang, F., et al., Crystal Structure of the *obese* protein leptin-E100, Nature 387: 206-209 (1997)).

As used herein, a conformational analog of OB protein is a molecule having substantially the same conformational characteristics of its three-dimensional structure that are required for activation of the OB receptor. Examples of such conformational characteristics include the conformation of the A major helix, the conformation of the D major helix, and the disulfide bond that maintains the geometrical relationship between the A and D major helices. Thus, amino acid substitutions that conserve the conformational characteristics of the molecule, for example, in the loop regions connecting the major helices, would produce conformational analogs to OB protein.

Peptides derived from the region of the OB protein from amino acid residues 106 to 140, as short as about 15 amino acids long, have been shown to be effective in mimicking the action of full-length recombinant OB protein (Grasso, P., et al., In vivo Effects of Leptin-Related Synthetic Peptides on Body Weight and Food Intake in Female *ob/ob* Mice: Localization of Leptin Activity to Domains Between Amino Acid Residues 106 - 140, Endocrinology 138: 1413-1418 (1997)). As used herein, "OB-related peptides" refers to natural or synthetic peptides derived from the region of the OB protein from about amino acid residue 106 to about amino acid residue 140 and includes conservative amino acid residue substitutions.

The term "antibody" in its various grammatical forms is used herein to refer to immunoglobulin molecules and immunologically active portions

of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope. Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab' and F(ab')₂. An antibody composition of the present invention is characterized as containing antibody molecules that immunoreact with OB protein or portions thereof.

An antibody composition of the present invention is typically produced by immunizing a mammal with a inoculum of OB protein or some fragment of OB protein, alone or in combination with a suitable adjuvant such as Freund's adjuvant, and thereby induce in the mammal antibody molecules having the appropriate immunospecificity. The antibody molecules are then collected from the mammal and isolated to the extent desired by well known techniques such as, for example, immunoaffinity chromatography. The antibody composition so produced can be used, inter alia, in the diagnostic methods and systems of the present invention or in the preparation of therapeutic compositions of the present invention.

Monoclonal antibody compositions can also be used with the present invention. A monoclonal antibody composition contains, within detectable limits, only one species of antibody combining site capable of effectively binding to OB protein. Thus, a monoclonal antibody composition of the present invention typically displays a single binding affinity for OB protein even though it may contain antibodies capable of binding proteins other than OB protein. Preferred monoclonal antibodies are those that bind to portions of the OB protein that are required for activation of the OB receptor, such as the A helix, the D helix, ,or regions of OB protein that maintain the relative positions of the A and D helices that are required for the activation of the OB receptor. Monoclonal antibodies against human OB protein have been described and their preparation was discussed in (Tsuruo, Y. et. al., Horm. Metab. Res. 28: 753-755 (1996)).

Monoclonal antibodies are also supplied commercially from vendors on a custom

order basis (e.g., Alpha Diagnostic International, Inc., San Antonio, TX). Purified polyclonal anti-OB antibodies are commercially available from several sources (R&D Systems, Minneapolis, MN; Research Diagnostics, Inc., Flanders, N.J.; Linco Research, Inc., St. Charles, MO; Affinity BioReagents, Inc., Golden, CO).

Determination of OB levels with OB antibodies is performed by assay methods, including ELISA, radioimmunoassay (RIA), Western blot analysis, and the like, that are familiar to one of ordinary skill in the art. The determined OB protein levels are then compared to normal levels for the state of the patient, e.g., fasting, time of day, body mass index (BMI), aerobic conditioning, gender, etc. For example, the normal range found for lean males at 8 a.m. was 12.0 ± 4.4 ng/ml (Sinha, M.K., et al., Nocturnal Rise of Leptin in Lean, Obese, and Non-Insulin-dependent Diabetes Mellitus Subjects, J. Clin. Invest. **97**: 1344-1347 (1996)). See, also Horn, R. et al., Radioimmunoassay for the detection of leptin in human serum, Exp. Clin. Endocrinol. Diabetes **104**: 454-458 (1996); McGregor, G.P., et al., Radioimmunological Measurement of Leptin in Plasma of Obese and Diabetic Human Subjects, Endocrinology **137**: 1501-1504 (1996). It has recently been found that OB protein is present in the circulation in both bound and free form, and that the ratio of the two forms is different in lean and obese subjects (Sinha, M.K., et al., Evidence of Free and Bound Leptin in Human Circulation. Studies in Lean and Obese Subjects and During Short-Term Fasting, J. Clin. Invest. **98**: 1277-1282 (1996)). The relation of free and bound forms to OB protein biological activity can be considered in the context of OB protein assays.

In an alternative embodiment, immunohistochemical assay of OB-R receptor numbers are performed on tissue biopsy materials using standard protocols. A preferred tissue biopsy is liver biopsy.

Therapeutic Applications

Embodiments of the present invention, including methods of administering to a patient compositions comprising OB-R agonist ligands are useful in treating conditions in which it is desirable to regulate or modify energy metabolism during a systemic inflammatory response. Suitable OB-R agonist ligands include recombinant OB protein, peptide conformational analogs of human OB protein comprising conservative substitutions of amino acid residues and OB-related peptides. A preferred OB-R agonist ligand is recombinant human OB protein. A suitable dosage range for recombinant human OB protein is from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight. OB-related peptides are used in a dosage range from about 0.1 microgram per kilogram body weight to about 5 micrograms per kilogram body weight, adjusting the dosage to account for art-recognized differences in potency and solubility (Grasso, P. et al., (1997)).

In a related embodiment, compositions comprising at least one OB-R expression inducer are useful for treating obesity and conditions in which there is an insufficient number of OB receptors, in which low copy number of OB receptors is a limiting factor or in which there is "OB resistance," i.e., a reduced effect of associated with a particular plasma concentration of OB protein.

In general, the OB-R expression inducer is administered in an amount from about 0.003 to about 20 micrograms per kilogram body weight. Suitable OB-R expression inducers include therapeutic cytokines used in cancer therapy, such as IL-1 α , IL-1 β , IL-6 and TNF- α . Suitable dosages and modes of administration are known in the art. For example, a suitable dosage ranges for IL-1 α is about 0.1 to about 6 micrograms/m²/day. A suitable dosage range for IL-1 β is about 3 to about 200 nanograms/kg/day. A suitable dosage range for IL-6 is about 0.5 to about 20 micrograms/kg/day, with a preferred dosage range for IL-6 being about 1 to about 5 micrograms/kg/day. The therapeutic cytokines may be administered singly or in combination. The mode of administration may be intravenous infusion over an extended time period or a single intravenous or

subcutaneous injection. The daily dose may be administered as a single dose or divided into multiple dose given at intervals during the day.

In a further embodiment, to counteract the possible toxic side effects of OB-R expression inducers such as therapeutic cytokines, such

5 substances are administered in a composition in combination with OB-R agonist ligands. Administration of such compositions is useful for conditions in which cytokines are normally administered for a therapeutic purpose such as tumor treatment, in order to provide effective protection by the OB-R agonist ligands from undesirable metabolic side effects. The up-regulation of the OB-R allows
10 for the complete therapeutic effect mediated by OB-R agonist ligands such as OB protein. A suitable dosage range for recombinant human OB protein is from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

15 In an alternative embodiment, the present invention describes the administration of OB antisera, polyclonal or monoclonal, for treating conditions marked by increased OB and/or increased OB-R activity. Such conditions are various wasting conditions or syndromes associated with several disease states or syndromes, including anorexia, amenorrhea, cachexia, chronic inflammatory conditions, AIDS and AIDS-related conditions. A suitable dosage range for anti-
20 OB protein antibodies is about 0.02 to about 15 milligrams / kg / day.

It has been found that OB protein is an important host defense factor against endotoxin stress. The protective effect of OB protein against endotoxin was not caused by suppressing the expression of major inflammatory mediators, since the mRNA levels of IL-1 α , IL-1 β , TNF- α , and iNOS in lung
25 and spleen were similar in all LPS-treated mice regardless of the experimental manipulations (Figure 16). A comparison of the four groups of mice revealed striking correlations among the OB protein available , the survival from endotoxin shock (Figures 10 and 11), the maintenance of body temperature (Figures 12 and 13), and the loss of body weight (Figures 14 and 15).

Anti-OB Ab-treated mice showed the least loss of body weight and had the most profound hypothermia even with a relatively low dose of LPS.

Conversely, OB-treated mice receiving a high dose of LPS maintained a higher body temperature than those control mice that received less LPS. The OB-treated

5 mice also had a greater weight loss than any reported in the literature (16% in the first 24 hours, compared with an average of 10% reported by other groups). The mice in these tests were age, sex and weight matched, fed the same diet, and, therefore, should have had very similar energy store. The different responses to endotoxemia described were likely due to differences in metabolic energy

10 mobilization and dissipation, which, in turn, were attributed to the experimental manipulation of circulating OB protein levels.

When the level of circulating OB protein is varied, the energy mobilized to resist endotoxin challenge is correspondingly altered, and the outcome of the host response to endotoxin stress is affected. *ob/ob* mice, lacking 15 OB protein due to a mutation in the *ob* gene, were very sensitive to LPS insult: a dose as low as 2 µg per gram of body weight caused a rapid fall of body temperature and death.

The results also suggest the existence of two pathways of thermogenesis and thermostasis. Anti-OB Ab treatment per se did not cause 20 hypothermia in normal mice, suggesting that the thermostasis under non-pathological conditions was largely OB protein-independent. However, when given LPS, the anti-OB Ab-treated mice developed profound hypothermia, indicating that the thermogenesis in response to endotoxemia had become OB protein dependent. A corollary of this model is that genetic defects affecting the 25 OB/OB-R pathway will have a severe hypothermic response to endotoxin. Indeed, *db/db* mice which carry a mutation in the OB-R gene, responded to a low dose of LPS injection in a manner very similar to that seen in *ob/ob* mice (data not shown), despite their increased level of OB expression.

Example 1: Induction of OB-R Expression by Administration of LPS

The injection of LPS and cytokines, substances that are associated with sepsis, septic shock or SIRS caused increases in the expression of the OB receptor in peripheral organs such as liver, but not in brain.

- 5 Intravenous injection of lipopolysaccharide (LPS), IL-1 β , TNF- α and IL-6 to mice induced OB receptor expression in the liver and other peripheral organs, but not in the central nervous system (CNS). To investigate the functional significance of the increased OB-R expression, an anti-OB antiserum was used to neutralize endogenous OB protein in mice prior to an LPS injection.
- 10 The neutralization of OB protein led to profound hypothermia, insignificant loss of body weight, and death in mice in response to an otherwise nonlethal dose of LPS. Conversely, mice administered recombinant mouse OB protein became more resistant to LPS and survived an otherwise lethal dose. The OB protein-treated mice maintained a relatively high body temperature and displayed
- 15 a dramatic weight loss. These results suggest that OB protein may promote energy mobilization to compensate for the increased energy consumption in endotoxemia, and that the OB/OB-R pathway may play an important role in critical host responses to inflammatory stress.

Methods:

- 20 In general, standard techniques or published modifications were used; see, generally, Sambrook, J., et al., Molecular Cloning A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press (1989). C57BL/6 mice, 5-8 weeks of age and 17-20 g of weight, were injected intravenously with either LPS (5 μ g per gram of body weight, List Biological Laboratory, Campbell, CA),
- 25 IL-1 β (R&D Systems, Minneapolis, MN), IL-6 (2.5 μ g, Pharmingen, San Diego, CA), or TNF- α (a gift from Genentech, San Francisco, CA). Animals were sacrificed at 0, 4, 8 or 24 hours, or 2, 3 or 5 days after the injection.

- 30 Tissue from various organs, including brain, liver and kidney, was dissected and snap-frozen in liquid nitrogen. Total RNA was prepared from the frozen tissues by a single-step method (Chomczynski, P. & Sacchi, N., Single-

Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction, Analytical Biochemistry **162**: 156-159 (1987).

The RNase protection assays were carried out as previously described (Feng, L., et al., Alternative Splicing of the NC1 Domain of the Human α 3(IV) Collagen Gene J. Biol. Chem. **269**: 2342-2348 (1994); Xia, Y., et al., LPS-Induced MCP-1, IL-1 β , and TNF- α mRNA Expression in Isolated Erythrocyte-Perfused Rat Kidney, Am. J. Physiol. **264**: F774-F780 (1993)). A ten microgram aliquot of total RNA pooled from three similarly treated mice was used for each sample in the RNase protection assay. The stored pooled samples 10 were dissolved in 10 μ l of 80% formamide, 0.4 M NaCl, 1 mM EDTA, and 40 mM piperazine-N,N'-bis(2-ethanesulfonic acid), heated to 85 degrees Celsius for 5 minutes. Each ten microgram sample was then hybridized with about 1×10^5 cpm (counts per minute) of the appropriate [32 P]UTP-labeled antisense riboprobe at 55 degrees Celsius for at least 10 hours. The unhybridized RNA was then 15 digested with 50 unit/ml RNase T1 (GIBCO/BRL, Gaithersburg, MD) and 24 μ g/ml RNase A at 30 degrees Celsius for one hour. The RNase was then digested with 625 μ g/ml proteinase K (Boehringer Mannheim, Indianapolis, IN) for 30 minutes at 37 degrees Celsius. After phenol-chloroform extraction and 20 sodium-acetate-ethanol precipitation, the protected hybridized RNA was denatured and electrophoresed on a 10% polyacrylamide gel. The gels were transferred to 3M Whatman filter paper, dried and exposed to Kodak X-Omat film. The resulting autoradiograms were developed in a Kodak X-Omat processor were used only for qualitative screening.

Radioactivity due to hybridization of target sequences with 32 P-labeled riboprobes was quantified by scanning the gels on an AMBIS 25 radioanalytic scanning system (AMBIS Systems, San Diego, CA).

An OB-Rb cDNA probe (from base 2548 to base 2835 of OB-Rb, Gen-Bank™ Accession No. U46135) was subcloned from a full-length mouse OB-Rb cDNA. The full-length mouse cDNA for the OB-R long form (OB-Rb)

was cloned from a mouse hypothalamus cDNA library (Stratagene, La Jolla, CA), and the sequence was verified against that of U46135.

The full-length mouse cDNA for the OB-R short form (OB-Ra) was cloned from a mouse lung cDNA Library (Stratagene, La Jolla, CA). A 224 bp probe that included base 1250 to base 1474 (as indicated on the OB-Rb sequence) of OB-Ra was used for the RNase protection assay. This fragment, which comprises a sequence that is shared by all variants of OB-R, was used as a probe for the total level of OB-R (OB_(t)).

The expression of other forms of OB-R mRNA was analyzed using selective probes for the respective different forms of OB-R. The designated probes provided full protection to their corresponding OB-R forms and partial protection for other OB-R forms. A probe derived from L32 (33-126, Gen-Bank™ Accession No. X06483), a housekeeping gene encoding ribosomal protein, was used as a control.

OB-Rc and OB-Re probes were cloned by reverse-transcription-PCR (RT-PCR) of total liver RNA from LPS-treated C57BL/6 mice. Protocols for RT-PCR are known in the art (for example, pages 15-13 - 15-15 of Ausubel, F.M., et al., Short Protocols in Molecular Biology, 2nd Edition, John Wiley and Sons, New York, (1992)).

One suitable protocol for RT-PCR is a modification of that previously described (Feng, L., et al., J. Biol. Chem. **269**: 2342-2348, 1994). The primers used in RT-PCR are listed in Table 1, below. Primer oligonucleotides were synthesized using an ABI model 380B synthesizer (Applied BioSystems, Foster City, Ca).

Table 1: PCR Primers

Sequence		
OB-Rc sense	5'-GCTATCGACAAGCAGCAGAAT-3'	(SEQ ID NO. 8)
5 OB-Rc antisense	5'-TGAACACAAACATAAACAGCCC-3'	(SEQ ID NO. 9)
OB-Re sense	5'-TGTTATATCTGGTTATTATTGAATGG-3'	(SEQ ID NO. 10)
10 OB-Re antisense	5'-CATTAATGATTTATTATCAGAATTGC-3'	(SEQ ID NO. 11)

First strand cDNA synthesis was performed using total liver RNA from LPS-treated C57BL/6 mice and murine leukemia virus reverse transcriptase with a random hexanucleotide primer. The 100 μ l reaction mixture contained standard enzyme buffer, 5 μ g of total RNA, 20 units of RNasin (RNase inhibitor), 500 pmol of hexanucleotide primer, 10 mM dithiothreitol, 1 mM of each dNTP, with 200 units of reverse transcriptase. Each reaction mixture was heated to 95 degrees Celsius for 10 minutes. PCR was then performed with separate aliquots of the reaction mixture with the appropriate primers for 35 cycles, using 60 degrees Celsius for annealing.

The cDNA segments used to generate riboprobes were excised by the appropriate restriction endonucleases and subcloned into the multiple cloning site of a standard transcription vector. Suitable transcription vectors include a vector chosen from the pGEM series (Promega, Madison, WI). Labelled single stranded riboprobes were synthesized using standard in vitro transcription protocols, either those provided by the manufacturer or other standard protocols (e.g. Ausubel, F.M., et al., pages 4-18 - 4-21) with the appropriate (e.g., SP6 or T7) bacteriophage RNA polymerase. The riboprobes contained regions corresponding to the vector polylinker in addition to the region corresponding to the target sequence, and thus were longer than the protected bands. The mouse ribosomal L32 gene, a constitutively expressed "housekeeping" gene, was used throughout the study as a control.

Results:

When LPS was administered to C57BL/6 mice, a strong induction of total OB-R expression (OB-R₍₀₎) was detected in a number of peripheral organs (Figure 1), but not in several areas of the central nervous system, such as the hypothalamus, that are known to express OB-R (compare Figure 1 and Figure 6). The increased expression of OB-R was most prominent in the liver, the major site of metabolic regulation. The increase of OB-R mRNA expression in the liver was LPS dose-dependent, and peaked between 24 and 48 hours post-LPS injection (Figure 1).

Unexpectedly, RNase protection assays using probes specific for alternatively spliced forms of OB-R mRNA revealed that the long form, OB-Rb, was also induced in the liver to a level comparable to that found in the *ob/ob* mouse hypothalamus and greater than that of the lean control mouse hypothalamus (Figure 2). However, the majority of hepatic OB-R were the OB-Ra, OB-Rc (Figure 3) and OB-Re (Figure 4) forms. OB-Rd expression in the liver was undetectable (data not shown).

In addition to LPS, OB-R expression was induced by the cytokines IL-6, IL-1 α and TNF- α (Figure 5). Contrary to a recent report (12), we found no detectable increase in OB expression in white adipose tissue in LPS-treated mice, but detected a distinct induction of OB mRNA expression in the adrenal gland (Figure 4). No OB mRNA expression was found in the brain, heart, lung, liver, kidney, spleen, muscle, stomach, duodenum, jejunum, ileum, or colon of LPS-treated mice (data not shown).

Example 2: Production of Recombinant OB Protein

Recombinant OB protein was expressed in *E. coli* using a prokaryotic expression vector and extracted from inclusion bodies. Other vectors and host cells systems, including eukaryotic cells, are known in the art and also suitable for the expression of OB protein. See, generally, Ausubel, F.M., et al. Short Protocols in Molecular Biology, 2nd Ed., pages 16-1 to 16-89.

The coding region of mouse OB cDNA (65-619, Gen-Bank™ Accession No.U18812) was cloned by RT-PCR of total RNA from C57BL/6 white adipose tissue. The coding region was subcloned in expression vector, pETM1 (Feng, L., et al., *J. Biol. Chem.* **269**: 2342-2348, 1994), to express a His-tagged recombinant mouse OB protein. The construction of pETM1 from the commercially available vector pET-11a (Novagen, Madison, WI) is illustrated on Figure 8.

After the expression of OB protein is induced, the bacteria were harvested and the inclusion bodies were extracted with a buffer containing 6M urea. The extract was loaded on a Ni-NTA affinity column (Qiagen, Chatsworth, CA) and the purification procedure was carried out as previously described (Feng, et al.(1994)). The protein was refolded on the column by adding refolding buffer containing 5 mM CaCl₂/20 mM Tris/0.2 NaCl with an urea gradient of 4 M - 0.5 M at a rate of about 0.5 ml/minute. After refolding, the protein was eluted with 80 mM imidazole/5 mM CaCl₂/20 mM Tris/0.2 NaCl/ 0.5 mM urea and then dialyzed against phosphate-buffered saline (PBS). Polyclonal antibodies was raised by immunizing a rabbit with the recombinant mouse OB and Freund's adjuvant using standard procedures. Antiserum was used in the following examples.

Example 3: Effects of Anti-OB Antibodies on Metabolism

Intravenous administration of antibodies directed against OB protein effectively opposes the effects of endogenous OB protein.

Recombinant mouse OB protein was produced in an *E. coli* expression system as described in Example 2, and was used to generate rabbit polyclonal anti-OB antibody. The antibody, when injected intravenously into mice, stimulated food intake, leading to rapid weight gain, and thus was effective in blocking OB protein function. The results are shown in Figure 9.

Female C57BL/6 mice, 6-8 weeks of age and 15-17 g of weight, were group housed four per cage and adapted to a 12:12 hour light: dark cycle (light from 6:00 to 18:00). Mice were given a daily intravenous injection of 0.2

ml anti-OB antiserum or preimmune rabbit sera ("vehicle") at 10 p.m., after their initial dark phase food intake. Their body weight was measured at 10 a.m. the next day.

5 The weight gain induced by anti-OB antiserum is illustrated in Figure 9. Data are expressed as mean \pm S.E.M. (N=8). While the weight of the control group remained essentially constant over the week, the anti-OB treated group showed a weight increase at the first weighing, which continued for the entire study period.

Example 4: Effects of Anti-OB Antibodies and Recombinant OB-Protein

10 on Response to Endotoxic Shock

The fact that the OB-R variants induced in the liver were predominantly short forms raised the question of functional relevance of the hepatic OB-R expression. OB-Rb is the main form expressed in the hypothalamus, while the choroid plexus expresses only OB-Ra. That the mutation in *db/db* mice affects OB-Rb, but not OB-Ra, suggests that OB-Rb is crucial for regulating food intake and OB-Ra may act as an OB protein transporter. Accordingly, the prominent expression of OB-R in the liver could initiate intracellular signal transduction or, alternatively, mediate the clearance of OB protein. We found that administration of neutralizing anti-OB antibody (Ab) or OB protein to LPS-treated mice distinguished between the two alternatives.

25 Male C57BL/6 mice, 5-8 weeks of age and 17-21 g of body weight, were used for this study. For antisera treatment, mice were given an i.v. injection of 200 μ l rabbit antisera. LPS at a dose of 6 μ g per gram of body weight was then co-injected with a second dose of anti-OB antibody to the pretreated mice. LPS was dissolved in antisera at a concentration of 0.6 mg/ml and was injected intravenously 4 hours after the initial antisera treatment. Food was retrieved from mouse cages during the 4-hour pretreatment period to prevent any food intake differences resulting from anti-OB antiserum-induced hyperphagia, and was added back after LPS injection.

While this dose of LPS was not lethal to C57BL/6 mice treated with preimmune rabbit serum, all the mice in the anti-OB Ab-treated group died within 40 hours. Figure 10 illustrates the results from three groups of mice: those pretreated with anti-OB antiserum (anti-OB, N=16), preimmune rabbit sera control, N=16), or three other unrelated rabbit antisera ("Anti-X", N=3 for each antiserum). This LPS sensitizing effect was specific for anti-OB Ab, since mice treated similarly with three other unrelated antibodies ("Anti-X") all survived (Figure 10).

In comparison, mice treated with OB protein (5 μ g per gram of body weight mOB, N=16) were able to survive a higher dose of LPS (10 μ g per gram of body weight) that was fatal to the control group of mice receiving the vehicle alone (control, N=16). Mouse OB protein and LPS were prepared in saline at a concentration of 0.5 mg/ml and 1 mg/ml, respectively, and injected intravenously into the mice. A vehicle solution used for OB protein dialysis was injected into control mice. To eliminate any circadian effect, experiments at different days were all started at the same hours. Mice were examined at 4-hour intervals post LPS injection for the first 24 hours, and survival was monitored for 7 days following the LPS injection. The results are shown in Figure 11. The dose of LPS killed all the mice in the control group within 24 hours. However, in the experimental group, OB protein treatment conferred mice complete resistance to this dose of endotoxin. The OB-treated mice displayed noticeably less severe symptoms of endotoxemia, remaining alert and responsive to touch and other manipulation, and recovering quickly.

The effects of both OB protein and anti-OB antibodies on body temperature and body weight were monitored in the same groups of mice. Core body temperature measurements were made by insertion of a thermistor probe (Yellow Springs Instrument, Yellow Springs, Ohio) into the colon, 1.5 cm beyond the rectum. Body weight measurements were made on a portable digital balance (Ohaus, Florham Park, NJ).

The mice receiving anti-OB antibodies, which ultimately died, showed lower body temperature (Figure 12) and less weight loss (Figure 14) than the corresponding control group than survived. Conversely, the mice receiving OB-protein, and which survived the endotoxic shock, showed higher body 5 temperature (Figure 13) and more weight loss (Figure 15) than the corresponding control group which succumbed.

While administration of both OB protein and anti-OB antibodies had significant effects on survival, body weight and body temperature, there was little effect on the expression of iNOS, IL-1 α , IL-1 β , and TNF- α mRNAs in lung 10 and spleen (Figure 16). Mice were treated as described in above (Figures 10-15).

RNase protection assays were performed as described in Example 1. Each sample was 5 μ g total RNA was used for each sample in the RNase protection assay. Riboprobes were produced as described in Example 1 based on the following cDNA fragments: IL-1 α (from base 172 to base 366, Accession No. 15 X01450, SEQ ID NO. 3), IL-1 β (from base 500 to base 671, Accession No. M15131, SEQ ID NO. 4), TNF- α (from base 428 to base 557, Accession No. M11731, SEQ ID NO. 5), mouse iNOS (from base 2404 to base 2698, Accession No. M92649, SEQ ID NO. 6), and L32 (from base 33 to base 126, Accession No. X064383, SEQ ID NO. 7).

20 Relatively little change in the pattern of expression of these markers was observed (Figure 16), suggesting that these the protective actions of OB proteins are direct and not indirect and mediated by these cytokines.

The foregoing is intended to be illustrative of the present invention, but not limiting. Numerous variations and modifications of the present invention 25 may be effected without departing from the true spirit and scope of the invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Feng, Lili
Chen, Sizhong
Xia, Yiyang
- (ii) TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO REGULATING ENERGY MOBILIZATION WITH OB PROTEIN AND OB ANTIBODIES
- (iii) NUMBER OF SEQUENCES: 11
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Olson & Hierl, Ltd.
 - (B) STREET: 20 North Wacker Drive, 36th Floor
 - (C) CITY: Chicago
 - (D) STATE: IL
 - (E) COUNTRY: US
 - (F) ZIP: 60606
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE: 04-JUN-1997
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 60/018,972
 - (B) FILING DATE: 04-JUN-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Olson, Arne M
 - (B) REGISTRATION NUMBER: 30,203
 - (C) REFERENCE/DOCKET NUMBER: TSRI540.1PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 312-580-1180
 - (B) TELEFAX: 312-580-1189

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2793 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGATCCCTGC	TCCAGCAGCT	GCAAGGTGCA	AGAAGAAGAA	GATCCCAGGG	AGGAAAATGT	60
GCTGGAGACC	CCTGTGTCGG	TTCCTGTGGC	TTTGGTCCTA	TCTGTCTTAT	GTTCAAGCAG	120
TGCCTATCCA	GAAAGTCCAG	GATGACACCA	AAACCCTCAT	CAAGACCATT	GTCACCAGGA	180
TCAATGACAT	TTCACACACG	CAGTCGGTAT	CCGCCAAGCA	GAGGGTCACT	GGCTTGGACT	240
TCATTCCTGG	GCTTCACCCCC	ATTCTGAGTT	TGTCCAAGAT	GGACCAGACT	CTGGCAGTCT	300
ATCAACAGGT	CCTCACCCAGC	CTGCCTTCCC	AAAATGTGCT	GCAGATAAGCC	AATGACCTGG	360
AGAATCTCCG	AGACCTCCTC	CATCTGCTGG	CCTTCTCCAA	GAGCTGCTCC	CTGCCTCAGA	420
CCAGTGGCCT	GCAGAACCCA	GAGAGCCTGG	ATGGCGTCCT	GGAAAGCCTCA	CTCTACTCCA	480
CAGAGGTGGT	GGCTTGAGC	AGGCTGCAGG	GCTCTCTGCA	GGACATTCTT	CAACAGTTGG	540
ATGTTAGCCC	TGAATGCTGA	AGTTTCAAAG	GCCACCAAGGC	TCCCAAGAAT	CATGTAGAGG	600
GAAGAACCT	TGGCTTCCAG	GGGTCTTCAG	GAGAAGAGAG	CCATGTGCAC	ACATCCATCA	660
TTCATTTCTC	TCCCTCTGT	AGACCACCCA	TCCAAAGGCA	TGACTCCACA	ATGCTTGACT	720
CAAGTTATCC	ACACAACCTC	ATGAGCACAA	GGAGGGGCCA	GCCTGCAGAG	GGGAACCTCA	780
CCTAGTTCTT	CAGCAAGTAG	AGATAAGAGC	CATCCCATCC	CCTCCATGTC	CCACCTGCTC	840
CGGGTACATG	TTCCTCCGTG	GGTACACGCT	TCGCTGCGGC	CCAGGAGAGG	TGAGGTAGGG	900
ATGGGTAGAG	CCTTTGGGCT	GTCTCAGAGT	CTTTGGGAGC	ACCGTGAAGG	CTGCATCCAC	960
ACACAGCTGG	AAACTCCAA	GCAGCACACG	ATGGAAGCAC	TTATTTATTT	ATTCTGCATT	1020
CTATTTTGG	TGGATCTGAA	GCAAGGCATC	AGCTTTTCA	GGCTTGGGG	GTCAGCCAGG	1080
ATGAGGAAGG	CTCCTGGGTT	GCTGCTTCA	ATCCTATTGA	TGGGTCTGCC	CGAGGCAAAC	1140
CTAATTTTG	AGTGAATGGA	AGGAAGGTTG	GGATCTTCCA	AACAAGAGTC	TATGCAGGTA	1200
GCGCTCAAGA	TTGACCTCTG	GTGACTGGTT	TTGTTTCTAT	TGTGACTGAC	TCTATCCAAA	1260
CACGTTGCA	CGGGCATTGC	CGGGAGCATA	GGCTAGGTTA	TTATCAAAG	CAGATGAATT	1320
TTGTCAAGTG	TAATATGTAT	CTATGTGCAC	CTGAGGGTAG	AGGATGTGTT	AGAGGGAGGG	1380
TGAAGGATCC	GGAAAGTGTTC	TCTGAATTAC	ATATGTGTGG	TAGGCTTTC	TGAAAGGGTG	1440
AGGCATTTTC	TTACCTCTGT	GGCCACATAG	TGTGGCTTTG	TGAAAAGGAC	AAAGGAGTTG	1500
ACTCTTCCG	GAACATTTGG	AGTGTACCAAG	GCACCCCTGG	AGGGGCTAAA	GCTACAGGCC	1560
TTTTGTTGGC	ATATTGCTGA	GCTCAGGGAG	TGAGGGCCCC	ACATTGAGA	CAGTGAGCCC	1620
CAAGAAAAGG	GTCCCTGGTG	TAGATCTCCA	AGGTTGTCCA	GGGTTGATCT	CACAATGCGT	1680

TTCTTAAGCA GGTAGACGTT TGCATGCCAA TATGTGGTTC TCATCTGATT GGTCATCCA	1740
AAGTAGAACCC CTGTCTCCCA CCCATTCTGT GGGGAGTTTT GTTCCAGTGG GAATGAGAAA	1800
TCACTTAGCA GATGGTCCTG AGCCCTGGC CAGCACTGCT GAGGAAGTGC CAGGGCCCCA	1860
GGCCAGGCTG CCAGAATTGC CCTTCGGGCT GGAGGATGAA CAAAGGGGCT TGGGTTTTTC	1920
CATCACCCCT GCACCCTATG TCACCATCAA ACTGGGGGC AGATCAGTGA GAGGACACTT	1980
GATGGAAAGC AATACACTTT AAGACTGAGC ACAGTTCGT GCTCAGCTCT GTCTGGTGCT	2040
GTGAGCTAGA GAAGCTCACC ACATACATAT AAAAATCAGA GGCTCATGTC CCTGTGGTTA	2100
GACCTACTC GCGGCGGTGT ACTCCACCAC AGCAGCACCG CACCGCTGGA AGTACAGTGC	2160
TGTCTCAAC AGGTGTGAAA GAACCTGAGC TGAGGGTGAC AGTGCCCAGG GGAACCTGTC	2220
TTGCAGTCTA TTGCATTTAC ATACCGCATT TCAGGGCACA TTAGCATCCA CTCCTATGGT	2280
AGCACACTGT TGACAATAGG ACAAGGGATA GGGGTTGACT ATCCCTTATC CAAAATGCTT	2340
GGGACTAGAA GAGTTTGGA TTTAGAGTC TTTTCAGGCA TAGGTATATT TGAGTATATA	2400
TAAAATGAGA TATCTTGGGG ATGGGGCCCA AGTATAAACAA TGAAGTTCAT TTATATTCA	2460
TAATACCGTA TAGACACTGC TTGAAGTGTAA GTTTTATACA GTGTTTTAAA TAACGTTGTA	2520
TGCATGAAAG ACGTTTTAC AGCATGAACC TGTCTACTCA TGCCAGCACT CAAAAACCTT	2580
GGGGTTTTGG AGCAGTTTGG ATCTTGGGTT TTCTGTTAAG AGATGGTTAG CTTATACCTA	2640
AAACCATAAT GGCAACACAGG CTGCAGGACC AGACTGGATC CTCAGCCCTG AAGTGTGCC	2700
TTCCAGCCAG GTCATACCCCT GTGGAGGTGA GCGGGATCAG GTTTGTGGT GCTAAGAGAG	2760
GAGTTGGAGG TAGATTTGG AGGATCTGAG GGC	2793

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3862 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GTGACCCAC GCGTCCGGAG GAATCGTTCT GCAAATCCAG GTGTACACCT CTGAAGAAAG	60
ATGATGTGTC AGAAATTCTA TGTGGTTTG TTACACTGGG AATTCTTTA TGTGATAGCT	120

GCACCTAACCC	TGGCATATCC	AATCTCTCCC	TGGAAATTAA	AGTTGTTTG	TGGACCACCG	180
AACACAACCG	ATGACTCCTT	TCTCTCACCT	GCTGGAGCCC	CAAACAATGC	CTCGGCTTTG	240
AAGGGGGCTT	CTGAAGCAAT	TGTTGAAGCT	AAATTTAATT	CAAGTGGTAT	CTACGTTCCCT	300
GAGTTATCCA	AAACAGTCTT	CCACTGTTGC	TTTGGGAATG	AGCAAGGTCA	AAAATGCTCT	360
GCACTCACAG	ACAACACTGA	AGGGAAGACA	CTGGCTTCAG	TAGTGAAGGC	TTCAGTTTT	420
CGCCAGCTAG	GTGTAAACTG	GGACATAGAG	TGCTGGATGA	AAGGGGACTT	GACATTATTC	480
ATCTGTCATA	TGGAGCCATT	ACCTAAGAAC	CCCTTCAAGA	ATTATGACTC	TAAGGTCCAT	540
CTTTTATATG	ATCTGCCTGA	AGTCATAGAT	GATTGCGCTC	TGCCCCCAC	GAAAGACAGC	600
TTTCAGACTG	TCCAATGCAA	CTGCAGTCTT	CGGGGATGTG	AATGTATGT	GCCGGTACCC	660
AGAGCCAAAC	TCAACTACGC	TCTTCTGATG	TATTTGGAAA	TCACATCTGC	CGGTGTGAGT	720
TTTCAGTCAC	CTCTGATGTC	ACTGCAGCCC	ATGCTTGTG	TGAAACCCGA	TCCACCCCTTA	780
GGTTTGCATA	TGGAAGTCAC	AGATGATGGT	AATTTAAAGA	TTTCTTGGGA	CAGCCAAACAA	840
ATGGCACCAT	TTCCGCTTCA	ATATCAGGTG	AAATATTTAG	AGAATTCTAC	AATGTAAGA	900
GAGGCTGCTG	AAATTGTCTC	AGCTACATCT	CTGCTGGTAG	ACAGTGTGCT	TCCTGGATCT	960
TCATATGAGG	TCCAGGTGAG	GAGCAAGAGA	CTGGATGGTT	CAGGAGTCTG	GAGTGACTGG	1020
AGTCACCTC	AAGTCTTAC	CACACAAGAT	GTTGTGTATT	TTCCACCCAA	AATTCTGACT	1080
AGTGTGGAT	CGAATGCTTC	TTTCATTGC	ATCTACAAAA	ACGAAAACCA	GATTATCTCC	1140
TCAAAACAGA	TAGTTGGTG	GAGGAATCTA	GCTGAGAAAA	TCCCTGAGAT	ACAGTACAGC	1200
ATTGTGAGTG	ACCGAGTTAG	CAAAGTTACC	TTCTCCAACC	TGAAAGCCAC	CAGACCTCGA	1260
GGGAAGTTA	CCTATGACGC	AGTGTACGTG	TGCAATGAGC	AGGCGTGCCA	TCACCGCTAT	1320
GCTGAATTAT	ACGTGATCGA	TGTCAATATC	AATATATCAT	GTGAAACTGA	CGGGTACTTA	1380
ACTAAAATGA	CTTGCAGATG	GTCACCCAGC	ACAATCCAAT	CACTAGTGGG	AAGCACTGTG	1440
CAGCTGAGGT	ATCACAGGCG	CAGCCTGTAT	TGTCCTGATA	GTCCATCTAT	TCATCCTACG	1500
TCTGAGCCCA	AAAATGCGT	CTTACAGAGA	GACGGCTTTT	ATGAATGTGT	TTTCCAGCCA	1560
ATCTTCTAT	TATCTGGCTA	TACAATGTGG	ATCAGGATCA	ACCATTCTT	AGGTTCACTT	1620
GAECTGCCAC	CAACGTGTGT	CCTTCCTGAC	TCCGTAGTAA	AACCACCTACC	TCCATCTAAC	1680
GTAAAAGCAG	AGATTACTGT	AAACACTGGA	TTATTGAAAG	TATCTTGGGA	AAAGCCAGTC	1740
TTTCCGGAGA	ATAACCTTCA	ATTCCAGATT	CGATATGGCT	TAAGTGGAAA	AGAAATACAA	1800
TGGAAGACAC	ATGAGGTATT	CGATGCAAAG	TCAAAGTCTG	CCAGCCTGCT	GGTGTCAAGAC	1860
CTCTGTGCAG	TCTATGTGGT	CCAGGTTCGC	TGCCGGCGGT	TGGATGGACT	AGGATATTGG	1920
AGTAATTGGA	GCAGTCCAGC	CTATACGTT	GTCATGGATG	TAAAAGTTCC	TATGAGAGGG	1980

CCTGAATTT GGAGAAAAAT GGATGGGAC GTTACTAAA AGGAGAGAAA TGTCACCTTG	2040
CTTTGGAAGC CCCTGACGAA AAATGACTCA CTGTGTAGTG TGAGGAGGTA CGTGGTGAAG	2100
CATCGTACTG CCCACAATGG GACGTGGTCA GAAGATGTGG GAAATCGGAC CAATCTCACT	2160
TTCCTGTGGA CAGAACCCAGC GCACACTGTT ACAGTTCTGG CTGTCAATTG CCTCGGCGCT	2220
TCCCTTGTGA ATTTAACCT TACCTTCTCA TGGCCCATGA GTAAAGTGAG TGCTGTGGAG	2280
TCACTCAGTG CTTATCCCCT GAGCAGCAGC TGTGTACATCC TTTCTGGAC ACTGTCACCT	2340
GATGATTATA GTCTGTTATA TCTGGTTATT GAATGGAAGA TCCTTAATGA AGATGATGGA	2400
ATGAAGTGGC TTAGAATTCC CTCGAATGTT AAAAAGTTTT ATATCCACGA TAATTTTATT	2460
CCCATCGAGA AATATCAGTT TAGTCTTAC CCAGTATTAA TGGAAGGAGT TGGAAAACCA	2520
AAGATAATTAA ATGGTTTCAC CAAAGATGCT ATCGACAAGC AGCAGAATGA CGCAGGGCTG	2580
TATGTCATTG TACCCATAAT TATTCCTCT TGTGTCCCTAC TGCTCGGAAC ACTGTTAATT	2640
TCACACCAGA GAATGAAAAA GTTGGTTTGG GACGATGTTG CAAACCCCAA GAATTGTTCC	2700
TGGGCACAAG GACTGAATTG CAAAAGCCT GAAACATTG AGCATCTTT TACCAAGCAG	2760
GCAGAACATCAG TGATATTG TGCTCTTCTT CTGGAGCCTG AACCCATTTC AGAAGAAATC	2820
AGTGTGATA CAGCTTGAA AAATAAAGAT GAGATGGTCC CAGCAGCTAT GGTCTCCCTT	2880
CTTTGACCA CACCAGACCC TGAAAGCAGT TCTATTGTA TTAGTGACCA GTGTAACAGT	2940
GCTAACTTCT CTGGGTCTCA GAGCACCCAG GTAACCTGTG AGGATGAGTG TCAGAGACAA	3000
CCCTCAGTTA AATATGCAAC TCTGGTCAGC AACGATAAAC TAGTGGAAAC TGATGAAGAG	3060
CAAGGGTTA TCCATAGTCC TGTCAGCAAC TGCATCTCCA GTAATCATTG CCCACTGAGG	3120
CAGTCTTCT CTAGCAGCTC CTGGGAGACA GAGGCCAGA CATTTCCTT TTTATCAGAC	3180
CAGCAACCCA CCATGATTTC ACCACAACCT TCATTCTCGG GGTTGGATGA GCTTTGGAA	3240
CTGGAGGGAA GTTTCCCTGA AGAAAATCAC AGGGAGAAGT CTGTCTGTTA TCTAGGAGTC	3300
ACCTCCGTCA ACAGAACAGA GAGTGGTGTG CTTTGACTG GTGAGGCAGG AATCCTGTGC	3360
ACATTCCCAG CCCAGTGTCT GTTCAGTGAC ATCAGGATCC TCCAGGAGAG ATGCTCACAC	3420
TTTGTAGAAA ATAATTGAG TTTAGGGACC TCTGGTGAGA ACTTTGTACC TTACATGCC	3480
CAATTCAAA CCTGTTCCAC GCACAGTCAC AAGATAATGG AGAATAAGAT GTGTGACTTA	3540
ACTGTGTAAT CTCATCCAAG AAGCCTCAAG GTTCCATTCC AGTAGAGCCT GTCATGTATA	3600
ATGTGTTCTT TTATTGTTGT GGATGTGGGA GACAAGTGTG AGAATCTAGT GTGAAAATGA	3660
TTGTTCCAA ACTAAGTGTG TCTATTCTT CTCAGTAATA CAATGAAACA TATGAGGAAG	3720
CCCTCATTAA TCTAGTAATG TAGATGGACT CTTACTGAAT ATATTCCCAA GATACTTGGG	3780
GAAGTCTCCC TAATTCTAGC TAAAAATAAA CCCAGGAATA GAACTACTAA ACACGTGAATC	3840

TGGAAAAAAA AAAAAAAA AG

3862

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1974 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AAGTCTCCAG GGCAGAGAGG GAGTCAACTC ATTGGCGCTT GAGTCGGCAA AGAAATCAAG	60
ATGGCCAAAG TTCCTGACTT GTTTGAAGAC CTAAAGAACT GTTACAGTGA AAACGAAGAC	120
TACAGTTCTG CCATTGACCA TCTCTCTCTG AATCAGAAAT CCTTCTATGA TGCAAGCTAT	180
GGCTCACTTC ATGAGACTTG CACAGATCAG TTTGTATCTC TGAGAACCTC TGAAACGTCA	240
AAGATGTCCA ACTTCACCTT CAAGGAGAGC CGGGTGACAG TATCAGCAAC GTCAAGCAAC	300
GGGAAGATTG TGAAGAAGAG ACGGCTGAGT TTCAGTGAGA CCTTCACTGA AGATGACCTG	360
CAGTCCATAA CCCATGATCT GGAAGAGACC ATCCAACCCA GATCAGCACC TTACACCTAC	420
CAGAGTGATT TGAGATACAA ACTGATGAAG CTCGTCAGGC AGAAGTTGT CATGAATGAT	480
TCCCTCAACC AAACTATATA TCAGGATGTG GACAAACACT ATCTCAGCAC CACTTGGTTA	540
AATGACCTGC AACAGGAAGT AAAATTGAC ATGTATGCCT ACTCGTCGGG AGGAGACGAC	600
TCTAAATATC CTGTTACTCT AAAAATCTCA GATTACAAC TGTTCTGAG CGCTCAAGGA	660
GAAGACCAGC CCGTGGCT GAAGGAGTTG CCAGAAACAC CAAACTCAT CACAGGTAGT	720
GAGACCGACC TCATTTCTT CTGGAAAAGT ATCAACTCTA AGAAACTACTT CACATCAGCT	780
GCTTATCCAG AGCTGTTAT TGCCACAAA GAACAAAGTC GGGTGCACCT GGCACGGGGA	840
CTGCCCTCTA TGACAGACTT CCAGATATCA TAAAAGCAGC CTTATTCGG GAGTCTATTG	900
ACTTGGGAAG TGCTGACAGT CTGTATGTAC CATGTACAGG AACCTTCCTC ACCCTGAGTC	960
ACTTGCACAG CATGTGCTGA GTCTCTGTAA TTCTAAATGA ATGTTACCC TCTTTGTAAG	1020
AGAAGAGCAA ACCCTAGTGG AGCCACCCCG ACATATGATA CTATCTGTTA TTTAAAGAG	1080
TACCCCTATAG TTTGCTCAGT ACTAATCATT TTAATTACTA TTCTGCATGG CATTCTTAGG	1140
AGGATCAAAA AGACTCTACA CATATTACAG ATGGGTTAAC AAAGGGATAA AACAACTGAA	1200

AAGCACACTC AATGCATTTG GAATATAAAT TCACAGACCA ATCTCACTGT GCACCTTCGG	1260
CTTCAAAATG CCAGTTGAGT AGGATAAAGG TATAAGAACT TAATGCTGTC ATTTCAAAA	1320
GGAAGGGGAC AATAGCTACA TCTTCCTAC CTCAGTGGGT TTTACTCCAG TGAGATCATT	1380
TGGATGAAAT CCTCCTGTAA CAGACCTCAA GAAGGGAGACA GACTGTTGAA TGTTATTTT	1440
AAGTTATTTT ATATATGTAT TTATAAATAT ATTTATGATA ATTATATTAT TTATGGAACA	1500
TCCTTAAATC CTCTGAGCTT GACAGGCATC CTCACAGCAG GATTTCTAG GTGGTCAGTT	1560
AGATATAGTT TCCTCTAGAG CACCATGCTA CAGACTTTAC ACTTTTCCA CAGCCACGAA	1620
GCTCTCTGTA CATTCCGTAA CTTGGGAGCC CTTTCATCAT GATCTTAATC TGTACTGTTT	1680
ACTTTGTTCA TCTAAAATGA TAATTGAGTC AGTCTTTTC CCTCCCATCC TTAAAGCTGT	1740
CTGGGTATTC TTACATCATT CAGTCTCACC TGTAACTAAC ACCAACCATC TAAAGATGGA	1800
AAGAGCTTAA CTGTGACAAC CACATCACTG TTACCTGAAG TTTCTTTCT AGAATGTAAT	1860
CAGTGTTCC CCTGGATTCC AATTTTTTT TCAAACCACA GTATCATGTA ACTATCAACA	1920
ATAACAATCA ACTCATTATT ATTAATCATA ATTAAATAAA ACAAGTTGA GCTG	1974

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1339 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TGCAGGGTTC GAGGCCTAAT AGGCTCATCT GGGATCCTCT CCAGCCAAGC TTCCCTGTGC	60
AAGTGTCTGA AGCAGCTATG GCAACTGTTG CTGAACCAA CTGTGAAATG CCACCTTTG	120
ACAGTGATGA GAATGACCTG TTCTTGAAAG TTGACGGACC CCAAAAGATG AAGGGCTGCT	180
TCCAAACCTT TGACCTGGC TGTCCAGATG AGAGCATCCA GCTTCAAATC TCACAGCAGC	240
ACATCAACAA GAGCTTCAGG CAGGCAGTAT CACTCATTGT GGCTGTGGAG AAGCTGTGGC	300
AGCTACCTGT GTCTTCCCG TGGACCTTCC AGGATGAGGA CATGAGCACC TTCTTTCC	360
TCATCTTGA AGAAGAGCCC ATCCTCTGTG ACTCATGGGA TGATGATGAT AACCTGCTGG	420
TGTGTGACGT TCCCATTAGA CAGCTGCACT ACAGGCTCCG AGATGAACAA CAAAAAAAGCC	480

TCGTGCTGTC GGACCCATAT GAGCTGAAAG CTCTCCACCT CAATGGACAG AATATCAACC	540
AACAAGTGAT ATTCTCCATG AGCTTTGTAC AAGGAGAACC AAGCAACGAC AAAATACCTG	600
TGGCCTTGGG CCTCAAAGGA AAGAATCTAT ACCTGTCTG TGTAATGAAA GACGGCACAC	660
CCACCCCTGCA GCTGGAGAGT GTGGATCCCA AGCAATAACCC AAAGAAGAACG ATGGAAAAGC	720
GGTTTGTCTT CAACAAGATA GAAGTCAAGA GCAAAGTGGA GTTTGAGTCT GCAGAGTTCC	780
CCAACCTGGTA CATCAGCACC TCACAAGCAG AGCACAAAGCC TGTCTTCCTG GGAAACAAACA	840
GTGGTCAGGA CATAATTGAC TTCACCATGG AATCTGTGTC TTCTAAAGT ATGGGCTGGA	900
CTGTTCTAA TGCCTTCCCC AGGGCATGTG AAGGAGCTCC CTTGTATGAA ATGAGCAGAC	960
AGCTCAATCT CTAGGACACT CCTTAGTCCT CGGCCAAGAC AGGTCGCTCA GGGTCACAAG	1020
AAACCATGGC ACATTCTGTT CAAAGAGAGC CTGTGTTCC TCCTTGCCTC TGATGGCAA	1080
CCACTTACCT ATTTATTTAT GTATTTATTG ATTGGTTGAT CTATTTAAGT TGATTCAAGG	1140
GGACATTAGG CAGCACTCTC TAGAACAGAA CCTAGCTGTC AACGTGTGGG GGATGAATTG	1200
GTCATAGCCT TGCACTTGAG GTCTTCATT GAAGCTGAGA ATAAATAGGT TCCTATAATA	1260
TGGATGAGAA TTTTATGAA TGAAGCATTA GCACATTGCT TTGATGAGTA TGAAATAAAT	1320
TTCATTAAC AACAAACA	1339

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1629 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GCTGAGGGAC TAGCCAGGAG GGAGAACAGA AACTCCAGAA CATCCTGGAA ATAGCTCCCA	60
GAAAAGCAAG CAGCCAACCA GGCAGGTTCT GTCCCTTTCA CTCACTGGCC CAAGGCGCCA	120
CATCTCCCTC CAGAAAAGAC ACCATGAGCA CAGAAAGCAT GATCCGCGAC GTGGAACTGG	180
CAGAAGAGGC ACTCCCCCAA AAGATGGGG GCTTCCAGAA CTCCAGGCAG TGCCTATGTC	240
TCAGCCTCTT CTCATTCCCTG CTTGTGGCAG GGGCCACCAAC GCTCTTCTGT CTACTGAAC	300
TCGGGGTGAT CGGTCCCCAA AGGGATGAGA AGTTCCAAA TGGCCTCCCT CTCATCAGTT	360

CTATGGCCCA GACCCTCAC A CTCAGATCAT CTTCTCAAAA TTGAGTGAC AAGCCTGTAG	420
CCCACGTCGT AGCAAACAC CAAGTGGAGG AGCAGCTGGA GTGGCTGAGC CAGCGCGCCA	480
ACGCCCTCCT GGCCAACGGC ATGGATCTCA AAGACAACCA ACTAGTGGTG CCAGCCGATG	540
GGTTGTACCT TGTCTACTCC CAGGTTCTCT TCAAGGGACA AGGCTGCCCC GACTACGTGC	600
TCCTCACCCA CACCGTCAGC CGATTGCTA TCTCATACCA GGAGAAAGTC AACCTCCTCT	660
CTGCCGTCAA GAGCCCCCTGC CCCAAGGACA CCCCTGAGGG GGCTGAGCTC AAACCCTGGT	720
ATGAGCCAT ATACCTGGGA GGAGTCTTCC AGCTGGAGAA GGGGGACCAA CTCAGCGCTG	780
AGGTCAATCT GCCCAAGTAC TTAGACTTTG CGGAGTCCGG GCAGGTCTAC TTTGGAGTCA	840
TTGCTCTGTG AAGGAAATGG GTGTTCATCC ATTCTCTACC CAGCCCCCAC TCTGACCCCT	900
TTACTCTGAC CCCTTTATTG TCTACTCCTC AGAGCCCCCA GTCTGTGTCC TTCTAACTTA	960
GAAAGGGGAT TATGGCTCAG AGTCCAACTC TGTGCTCAGA GCTTCAACA ACTACTCAGA	1020
AACACAAGAT GCTGGGACAG TGACCTGGAC TGTGGGCCTC TCATGCACCA CCACCCACGG	1080
AATCGAGAAA GAGCTATCAA TCTGGAATTG ACTGGAGCCT CGAATGTCCA TTCCTGAGTT	1140
CTGCAAAGGG AGAGTGGTCA GTTGCCTCT GTCTCAGAAT GAGGCTGGAT AAGATCTCAG	1200
GCCTTCCTAC CTTCAGACCT TTCCAGACTC TTCCCTGAGG TGCAATGCAC AGCCTTCCTC	1260
ACAGAGCCAG CCCCCCTCTA TTTATATTG CACTTATTAT TTATTATTTA TTTATTATTT	1320
ATTTATTTGC TTATGAATGT ATTTATTTGG AAGGCCGGGG TGTCTGGAG GACCCAGTGT	1380
GGGAAGCTGT CTTCAGACAG ACATGTTTC TGTAAAACG GAGCTGAGCT GTCCCCACCT	1440
GGCCTCTCTA CCTTGTTGCC TCCTCTTTG CTTATTTTA AAACAAAATA TTTATCTAAC	1500
CCAATTGTCT TAATAACGCT GATTGGTGA CCAGGCTGTC GCTACATCAC TGAACCTCTG	1560
CTCCCCACGG GAGCCGTGAC TGTAATTGCC CTACGGGTCA TTGAGAGAAA TAAAGATCGC	1620
TTGGAAAAG	1629

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4110 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GAGACTCTGG	CCCCACGGGA	CACAGTGTCA	CTGGTTGAA	ACTTCTCAGC	CACCTTGGTG	60
AAGGGACTGA	GCTGTTAGAG	ACACTTCTGA	GGCTCCTCAC	GCTTGGGTCT	TGTTCACTCC	120
ACGGAGTAGC	CTAGTCAACT	GCAAGAGAAC	GGAGAACGTT	GGATTTGGAG	CAGAAGTGCA	180
AAGTCTCAGA	CATGGCTTGC	CCCTGGAAGT	TTCTCTCAA	AGTCAAATCC	TACCAAAGTG	240
ACCTGAAAGA	GGAAAAGGAC	ATTAACAACA	ACGTGAAGAA	AACCCCTTGT	GCTGTTCTCA	300
GCCCAACAAT	ACAAGATGAC	CCTAAGAGTC	ACCAAAATGG	CTCCCCGAG	CTCCTCACTG	360
GGACAGCACA	GAATGTTCCA	GAATCCCTGG	ACAAGCTGCA	TGTGACATCG	ACCCGTCCAC	420
AGTATGTGAG	GATCAAAAAC	TGGGGCAGTG	GAGAGATTTT	GCATGACACT	CTTCACCACA	480
AGGCCACATC	GGATTCACT	TGCAAGTCCA	AGTCTGCTT	GGGGTCCATC	ATGAACCCCCA	540
AGAGTTTGAC	CAGAGGACCC	AGAGACAAGC	CTACCCCTCT	GGAGGAGCTC	CTGCCTCATG	600
CCATTGAGTT	CATCAACCAG	TATTATGGCT	CCTTTAAAGA	GGCAAAAATA	GAGGAACATC	660
TGGCCAGGCT	GGAAAGCTGTA	ACAAAGGAAA	TAGAAACAAC	AGGAACCTAC	CAGCTCACTC	720
TGGATGAGCT	CATCTTGCC	ACCAAGATGG	CCTGGAGGAA	TGTCCCTCGC	TGCATCGGCA	780
GGATCCAGTG	GTCCAACCTG	CAGGTCTTG	ACGCTCGAA	CTGTAGCACA	GCACAGGAAA	840
TGTTTCAGCA	CATCTGCAGA	CACATACTTT	ATGCCACCAA	CAATGGCAAC	ATCAGGTCGG	900
CCATCACTGT	GTTCCCCCAG	CGGAGTGACG	GCAAACATGA	CTTCAGGCTC	TGGAATTAC	960
AGCTCATCCG	GTACGCTGGC	TACCAGATGC	CCGATGGCAC	CATCAGAGGG	GATGCTGCCA	1020
CCTTGGAGTT	CACCCAGTTG	TGCATCGACC	TAGGCTGGAA	GCCCCGCTAT	GGCCGTTTG	1080
ATGTGCTGCC	TCTGGTCTTG	CAAGCTGATG	GTCAAGATCC	AGAGGTCTT	GAAATCCCTC	1140
CTGATCTTGT	GTTGGAGGTG	ACCATGGAGC	ATCCCAAGTA	CGAGTGGTTC	CAGGAGCTCG	1200
GGTTGAAGTG	GTATGCACTG	CCTGCCGTGG	CCAACATGCT	ACTGGAGGTG	GGTGGCCTCG	1260
AATTCCCAGC	CTGCCCTTC	AATGGTTGGT	ACATGGCAC	CGAGATTGGA	GTTCGAGACT	1320
TCTGTGACAC	ACAGCGCTAC	AACATCCTGG	AGGAAGTGGG	CCGAAGGATG	GGCCTGGAGA	1380
CCCACACACT	GGCCTCCCTC	TGGAAAGACC	GGGCTGTCAC	GGAGATCAAT	GTGGCTGTGC	1440
TCCATAGTTT	CCAGAAGCAG	AATGTGACCA	TCATGGACCA	CCACACAGCC	TCAGAGTCCT	1500
TCATGAAGCA	CATGCAGAAT	GAGTACCGGG	CCCGTGGAGG	CTGCCCGCA	GACTGGATT	1560
GGCTGGTCCC	TCCAGTGTCT	GGGAGCATCA	CCCCTGTGTT	CCACCAGGAG	ATGTTGAACT	1620
ATGTCCTATC	TCCATTCTAC	TACTACCAGA	TCGAGCCCTG	GAAGACCCAC	ATCTGGCAGA	1680
ATGAGAAGCT	GAGGCCAGG	AGGAGAGAGA	TCCGATTTAG	AGTCTGGTG	AAAGTGGTGT	1740
TCTTGCTTC	CATGCTAATG	CGAAAGGTCA	TGGCTTCACG	GGTCAGAGCC	ACAGTCCTCT	1800

TTGCTACTGA GACAGGGAAG TCTGAAGCAC TAGCCAGGGA CCTGGCCACC TTGTCAGCT	1860
ACGCCCTCAA CACCAAGGTT GTCTGCATGG ACCAGTATAA GGCAAGCACC TTGGAAGAGG	1920
AGCAACTACT GCTGGTGGTG ACAAGCACAT TTGGGAATGG AGACTGTCCC AGCAATGGC	1980
AGACTCTGAA GAAATCTCTG TTCATGCTTA GAGAACTCAA CCACACCTTC AGGTATGCTG	2040
TGTTTGGCCT TGGCTCCAGC ATGTACCCCTC AGTTCTGCAGC CTTTGCTCAT GACATCGACC	2100
AGAACGCTGTC CCACCTGGGA GCCTCTCAGC TTGCCCAAC AGGAGAAGGG GACGAACCTCA	2160
GTGGGCAGGA GGATGCCTTC CGCAGCTGGG CTGTACAAAC CTTCCGGGCA GCCTGTGAGA	2220
CCTTTGATGT CCGAAGCAAA CATCACATTC AGATCCCAGA ACGCTTCACT TCCAATGCAA	2280
CATGGGAGCC ACAGCAATAT AGGCTCATCC AGAGCCCGGA GCCTTAGAC CTCAACAGAG	2340
CCCTCAGCAG CATCCATGCA AAGAACGTGT TTACCATGAG GCTGAAATCC CAGCAGAAC	2400
TGCAGAGTGA AAAGTCCAGC CGCACCAACCC TCCTCGTTCA GCTCACCTTC GAGGGCAGCC	2460
GAGGGCCAG CTACCTGCCT GGGGAACACC TGGGGATCTT CCCAGGCAAC CAGACCGCCC	2520
TGGTGCAGGG AATCTGGAG CGAGTTGTGG ATTGTCTTAC ACCACACCAA ACTGTGTGCC	2580
TGGAGGTTCT GGATGAGAGC GGCAGCTACT GGGTCAAAGA CAAGAGGCTG CCCCCCTGCT	2640
CACTCAGCCA AGCCCTCACC TACTTCCTGG ACATTACGAC CCCTCCCACC CAGCTGCAGC	2700
TCCACAAGCT GGCTCGCTTT GGACGGACG AGACGGATAG GCAGAGATTG GAGGCCCTGT	2760
GTCAGCCCTC AGAGTACAAT GACTGGAAGT TCAGCAACAA CCCCACGTTC CTGGAGGTGC	2820
TTGAAGAGTT CCCTTCCCTTG CATGTGCCCG CTGCCTTCCT GCTGTCGCAG CTCCCTATCT	2880
TGAAGCCCCG CTACTACTCC ATCAGCTCCT CCCAGGACCA CACCCCTCG GAGGTTCAC	2940
TCACTGTGGC CGTGGTCACC TACCGCACCC GAGATGGTCA GGGTCCCCTG CACCATGGTG	3000
TCTGCAGCAC TTGGATCAGG AACCTGAAGC CCCAGGACCC AGTGCCTGC TTTGTGCGAA	3060
GTGTCAGTGG CTTCCAGCTC CCTGAGGACCC CCTCCCAGCC TTGCATCCTC ATTGGCCTG	3120
GTACGGGCAT TGCTCCCTTC CGAAGTTCT GGCAGCAGCG GCTCCATGAC TCCCAGCACA	3180
AAGGGCTCAA AGGAGGCCGC ATGAGCTTGG TGTTTGGGTG CCGGCACCCG GAGGAGGACC	3240
ACCTCTATCA GGAAGAAATG CAGGAGATGG TCCGCAAGAG AGTGTGTTC CAGGTGCACA	3300
CAGGCTACTC CCGGCTGCC GGCAAAACCA AGGTCTACGT TCAGGACATC CTGCAAAAGC	3360
AGCTGGCCAA TGAGGTACTC AGCGTTCTCC ACGGGGAGCA GGGCCACCTC TACATTTGCG	3420
GAGATGTGCG CATGGCTCGG GATGTGGCTA CCACATTGAA GAAGCTGGTG GCCACCAAGC	3480
TGAACTTGAG CGAGGAGCAG GTGGAAGACT ATTTCTTCCA GCTCAAGAGC CAGAAACGTT	3540
ATCATGAAGA TATCTTCGGT GCAGTCTTTT CCTATGGGC AAAAAAGGGC AGGCCCTTGG	3600
AGGAGCCCAA AGCCACGAGG CTCTGACAGC CCAGAGTTCC AGCTTCTGGC ACTGAGTAAA	3660

GATAATGGTG AGGGGCTTGG GGAGACAGCG AAATGCAATC CCCCCCAAGC CCCTCATGTC	3720
ATTCCCCCCT CCTCCACCCCT ACCAAGTAGT ATTGTATTAT TGTGGACTAC TAAATCTCTC	3780
TCCTCTCCTC CCTCCCCCTCT CTCCCTTCC TCCCTTCTTC TCCACTCCCC AGCTCCCTCC	3840
TTCTCCTTCT CCTCCTTGC CTCTCACTCT TCCTTGGAGC TGAGAGCAGA GAAAAACTCA	3900
ACCTCCTGAC TGAAGCACTT TGGGTGACCA CCAGGAGGCA CCATGCCGCC GCTCTAATAC	3960
TTAGCTGCAC TATGTACAGA TATTATACT TCATATTAA GAAAACAGAT ACTTTGTCT	4020
ACTCCCAATG ATGGCTTGGG CCTTTCTGT ATAATTCTT GATGAAAAAT ATTTATATAA	4080
AATACATTTT ATTTTAATCA AAAAAAAAAA	4110

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 465 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Rattus norvegicus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GGCATCATGG CTGCCCTTCG GCCTCTGGTG AAGCCCAAGA TCGTCAAAAA GAGGACCAAG	60
AAGTTCATCA GGCACCAGTC GGACCGATAT GTGAAAATTA AGCGAAACTG GCGGAAACCC	120
AGAGGCATCG ACAACAGGGT GCGGAGAAGA TTCAAGGGCC AGATCCTGAT GCCAACATT	180
GGTTACGGGA GTAACAAGAA AACCAAGCAC ATGCTGCCTA GCGGCTTCCG GAAGTTCTG	240
GTCCACAATG TCAAGGAGCT GGAAGTGCTG CTGATGTGCA ACAAAATCTTA CTGTGCTGAG	300
ATTGCTCACA ATGTGTCTC TAAGAACCGA AAAGCCATCG TAGAAAGAGC AGCACAGCTG	360
GCCATCAGAG TCACCAATCC CAACGCCAGG CTACGCAGCG AAGAGAATGA ATAGATGGCT	420
TGTGTGCCTG TTTTGTGTTA AAATAAAACC ACAAAACTG CCAAA	465

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCTATCGACA AGCAGCAGAA T

21

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TGAACACAAAC AACATAAAGC CC

22

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TGTTATATCT GGTTATTATT GAATGG

26

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CATTAAATGA TTTATTATCA GAATTGC

27

WE CLAIM:

1. A method for treating a patient having a condition in which regulating energy metabolism during a systemic inflammatory response is desired, comprising administering a composition having a physiologically effective amount of at least one OB-R agonist ligand.

5 2. The method of claim 1 wherein the OB-R agonist ligand is.. recombinant human OB protein.

10 3. The method of claim 2 wherein the amount of recombinant human OB protein administered is from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

4. The method of claim 1 wherein the OB-R agonist ligand is a peptide conformational analog of human OB protein comprising conservative substitutions of amino acid residues.

15 5. The method of claim 1 wherein the OB-R agonist ligand is an OB-related peptide.

6. The method of claim 1 wherein the condition is sepsis.

7. The method of claim 1 wherein the condition is systemic inflammatory response syndrome.

20 8. A composition for treating a patient having a condition in which regulating energy metabolism during a systemic inflammatory response is desired, comprising a physiologically effective amount of at least one OB-R agonist ligand.

9. The composition of claim 8 wherein the OB-R agonist ligand is recombinant human OB protein.

25 10. The composition of claim 9 wherein the amount of recombinant human OB protein per dose is from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

11. The composition of claim 8 wherein the OB-R agonist ligand is a peptide conformational analog of human OB protein comprising conservative substitutions of amino acid residues.

12. The composition of claim 8 wherein the OB-R agonist 5 ligand is an OB-related peptide.

13. The composition of claim 8 wherein the condition is sepsis.

14. The composition of claim 8 wherein the condition is systemic inflammatory response syndrome.

15. A composition for the amelioration of the toxicity of 10 therapeutic cytokines comprising a physiologically effective amount of an OB-R agonist ligand.

16. The composition of claim 15 wherein the OB-R agonist ligand is recombinant human OB protein.

17. The composition of claim 15 wherein the amount of 15 recombinant human OB protein per dose is 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

18. A method for the treatment of a patient having obesity comprising the steps of:

administering at least one OB-R expression inducer; and

20 administering a physiologically effective amount of an OB-R agonist ligand.

19. The method of claim 18 wherein the OB-R expression inducer is a compound chosen from the group consisting of LPS, IL-1 α , IL-1 β , TNF- α and IL-6.

25 20. The method of claim 18 wherein the OB-R expression inducer and the OB-R agonist ligand are administered at a different times.

21. The method of claim 18 wherein the OB-R expression inducer is administered in an amount from about 0.003 to about 20 micrograms per kilogram body weight.

22. The method of claim 18 wherein the OB-R agonist ligand is administered in an amount from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

5 23. The method of claim 18 wherein the OB-R agonist ligand is recombinant human OB protein.

24. The method of claim 23 wherein the recombinant human OB protein is administered in an amount from about 1 micrograms per kilogram body weight to about 50 micrograms per kilogram body weight.

10 25. The method of claim 18 wherein the OB-R expression inducer is IL-6.

26. The method of claim 25 wherein IL-6 is administered in an amount from about 0.5 to about 20 micrograms per kilogram body weight.

27. A method for the treatment of a patient having a condition characterized by OB resistance, comprising the steps of:

15 administering IL-6 in an amount from about 0.5 to about 20 micrograms per kilogram body weight; and

administering recombinant human OB protein in an amount from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

20 28. A composition suitable for the treatment of obesity comprising:

at least one therapeutic cytokine capable of increasing the expression of the OB receptor;

25 a physiologically effective amount of an OB-R agonist ligand; and a pharmaceutically acceptable excipient.

29. The composition of claim 28 wherein the therapeutic cytokine capable of increasing the expression of the OB receptor and the OB-R agonist ligand are packaged separately.

30. The composition of claim 28 wherein the therapeutic cytokine is about 0.5 to about 20 micrograms per kilogram body weight IL-6.

31. The composition of claim 29 wherein the OB-R agonist ligand is administered in a dose of about 1 micrograms per kilogram body weight to about 50 micrograms per kilogram body weight recombinant human OB protein.

5 32. An assay kit for a disease marker in a sample for a systemic inflammatory response in a patient comprising:

an antibody capable of binding to OB protein; and
a detection means for determining the amount of the antibody bound to OB protein.

10 33. A method for assaying a disease marker for an inflammatory response in a patient comprising:

mixing a portion of the sample with an antibody capable of binding to OB protein; and
detecting the amount of antibody bound to OB protein.

15 34. A composition suitable for the treatment of anorexia, cachexia or other wasting condition comprising a physiologically effective amount of antibody capable of binding OB protein.

35. The method for the treatment of anorexia, cachexia or other wasting condition comprising administering a physiologically effective amount of antibody capable of binding OB protein in an amount from about 0.02 to about 15 milligrams per kilogram body weight per day.

1 / 12




FIG. 1

2 / 12





FIG. 2

FIG. 3
SUBSTITUTE SHEET (RULE 26)

3 / 12




FIG. 4

4 / 12




FIG. 5

5 / 12



6 / 12





FIG. 7

7 / 12

**FIG. 8**

8 / 12




FIG. 9

9 / 12




FIG. 10




FIG. 11

10 / 12




FIG. 12




FIG. 13

11 / 12




FIG. 14




FIG. 15



12 / 12




FIG. 16

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/09684

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 38/00, 45/05, 38/19, 39/395
 US CL :514/2, 8, 12; 424/85.1,158.1, 145.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 8, 12; 424/85.1,158.1, 145.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, DIALOG, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/05309 A3 (THE ROCKEFELLER UNIVERSITY) 22 February 1996, (22-02-96), see the claims.	1-35
X, P	WO 96/35787 A1 (CHIRON CORPORATION) 14 November 1996 (14-11-96), see entire document, and claims.	1-35
X	PELLELYMOUNTER et al. Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice. Science, 28 July 1995, Vol. 269, see pages 540-543.	8-17, 18-26
X	HALAAS et al. Weight-Reducing Effects on the Plasma Protein Encoded by the obese Gene. Science, 28 July 1995, Vol. 269, see pages 543--547.	8-17, 18-26

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 SEPTEMBER 1997

Date of mailing of the international search report

23 SEP 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231Authorized officer
GARNETTE D. DRAPER
Telephone No. (703) 308-0196

Facsimile No. (703) 305-3230

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/09684

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GRUNFELD et al. Endotoxin and Cytokines Induce Expression of Leptin, the ob Gene Product, in Hamsters. Journal of Clinical Investigations. Clin. Invest. May 1996, Vol. 97, see pages 2152-2157.	1-35
X, P	SARRAF et al. Multiple Cytokines and Acute Inflammation Raise Mouse Leptin Levels: Potential Role in Inflammatory Anorexia. Journal of Experimental Medicine. 06 January 1997, Vol. 185, Number 1, see pages 171-175.	1-35
X, P	ROUBENOFF et al. TNF-alpha and leptin in adjuvant arthritis (AA): Implications for inflammatory cachexia. Arthritis & Rheumatism, September 1996, Vol. 39, No. 9 (supplement), see Abstract No. 302, page s77.	1-35
A, P	GAINSFORD et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc. Natl. Acad. Sci. December 1996, Vol. 93, see pages 14564-14568.	1-35
A, P	BENNETT et al. A role for leptin and its cognate receptor in hematopoiesis. Current Biology, 1996, Vol. 6, No. 9, see pages 1178-1180.	1-35

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference TSRI 540.1 PCT	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US97/09684	International filing date (day/month/year) 04 JUNE 1997	Priority date (day/month/year) 04 JUNE 1996
International Patent Classification (IPC) or national classification and IPC IPC(6): A61K 38/00, 45/05, 38/19, 39/395 and US Cl.: 514/2, 8, 12; 424/85.1, 158.1, 145.1		
Applicant THE SCRIPPS RESEARCH INSTITUTE		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 4 sheets.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 30 DECEMBER 1997	Date of completion of this report 17 AUGUST 1998
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer GARNETTE D. DRAPER 
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US97/09684

L Basis of the report

1. This report has been drawn on the basis of (Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):

 the international application as originally filed. the description, pages 1-38 _____, as originally filed.pages NONE _____, filed with the demand.pages NONE _____, filed with the letter of _____.

pages _____, filed with the letter of _____.

 the claims, Nos. 1-35 _____, as originally filed.Nos. NONE _____, as amended under Article 19.Nos. NONE _____, filed with the demand.Nos. NONE _____, filed with the letter of _____.

Nos. _____, filed with the letter of _____.

 the drawings, sheets/fig 1-16 _____, as originally filed.sheets/fig NONE _____, filed with the demand.sheets/fig NONE _____, filed with the letter of _____.

sheets/fig _____, filed with the letter of _____.

2. The amendments have resulted in the cancellation of:

 the description, pages NONE _____. the claims, Nos. NONE _____. the drawings, sheets/fig NONE _____.

3. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the **Supplemental Box** Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US97/09684

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims <u>1-7, 18-27</u>	YES
	Claims <u>8-17, 28-35</u>	NO
Inventive Step (IS)	Claims <u>1-7, 18-27</u>	YES
	Claims <u>8-17, 28-35</u>	NO
Industrial Applicability (IA)	Claims <u>1-35</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 8-17 lack novelty under PCT Article 33(2) as being anticipated by, or in the alternative lack an inventive step under PCT Article 33(3) as being obvious over The Rockefeller University ('309), Grunfeld et al, Pelleymounter et al or Halaas et al.

The claims are directed to compositions of the Ob protein or an Ob agonist ligand, wherein the claims recited several intended uses for the composition such as regulating energy metabolism during a systemic inflammatory response, or for ameliorating the toxicity of cytokines. Each of the prior art disclose composition of the Ob protein or related protein that are agonist, but the protein is disclosed for use in a different method from those of the claims. The prior art anticipate or render obvious the claims for a composition of the Ob protein irrespective of statements of intended for the composition. Furthermore, a composition per se is not distinct even if it is used for a different purpose or in a different method. Therefore, the burden is on the applicants to prove that the prior art composition does not possess the properties for methods of treatment consistent with the claims.

Claims 32-35 lack novelty under PCT Article 33(2) as being anticipated by, or in the alternative lack an inventive step under PCT Article 33(3) as being obvious The Rockefeller University ('309).

In addition to the above teachings, Friedman et al also disclose antibodies to the ob protein and teach that these antibodies can be used in diagnostic methods to detect for disorders associated with the Ob protein. Thus, the prior art appears to meet the claim limitation, irrespective of the fact that the language used to define the invention differs, and irrespective of statements of intended use for the antibody composition. Also taught is that the antibodies can be used to antagonist the undesired effect of the leptin, therefore to use the antibodies to treat low weight disorders is also anticipated or obvious from such teachings.

Claims 28-31 lack novelty under PCT Article 33(2) as being (Continued on Supplemental Sheet.)



Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):

anticipated by, or in the alternative lack an inventive step under PCT Article 33(3) as being obvious Grunfeld et al.

Similar to the above, these claims are directed to a composition of the Ob protein and a cytokine, and wherein the claims recite specific statements of intended use for the composition. Grunfeld et al teach that endotoxin and cytokines induce the expression of leptin/ob in response to infection, and with this discovery, they provide compositions of the Ob protein and cytokines such as TNF, IL-1, IL-6, IL-8 and IFN. The prior art anticipate or render obvious the claims for a composition of the Ob protein and a cytokine irrespective of statements of intended for the composition. Furthermore, the composition per se is not distinct even if it is used for a different purpose or in a different method. Therefore, the burden is on the applicants to prove that the prior art composition does not possess the properties for methods of treatment consistent with the claims.

Claims 1-7, 18-31 lack an inventive step under PCT Article 33(2) as being obvious Grunfeld et al.

The disclosure of Grunfeld et al has been set forth above. Since the prior art teach that endotoxin such as LPS and cytokines induce expression of the Ob protein in response to infection. In view of the well known fact that many infections are associated with or are accompanied by inflammations, at the time of the invention it would have been obvious to use the ob protein alone or in conjunction with the endotoxin or a cytokine to regulate energy metabolism during inflammation that are associated with the ob protein.

Claims 1-35 the criteria set out in PCT Article 33(4); and claims 1-7 and 18-27 meet the criteria set out in PCT Article 33(2) because the prior art does not expressly teach the use of an Ob-R inducer with a cytokine and the Ob/leptin to treat obesity as claimed.

NEW CITATIONS

NONE

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION
(PCT Rule 61.2)

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 16 February 1998 (16.02.98)	
International application No. PCT/US97/09684	Applicant's or agent's file reference TSRI 540.1 PCT
International filing date (day/month/year) 04 June 1997 (04.06.97)	Priority date (day/month/year) 04 June 1996 (04.06.96)
Applicant FENG, Lili et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

30 December 1997 (30.12.97)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer J. Leitao Telephone No.: (41-22) 338.83.38
---	---

PATENT COOPERATION TREATY

JB

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

Date of mailing (day/month/year) 20 February 1998 (20.02.98)

To: CEPURITIS, Talivaldis Olson & Hierl, Ltd. 36th floor 20 North Wacker Drive Chicago, IL 60606 ETATS-UNIS D'AMERIQUE
--

Applicant's or agent's file reference TSRI 540.1 PCT

IMPORTANT NOTIFICATION

International application No. PCT/US97/09684

International filing date (day/month/year) 04 June 1997 (04.06.97)

1. The following indications appeared on record concerning:

<input checked="" type="checkbox"/> the applicant	<input checked="" type="checkbox"/> the inventor	<input type="checkbox"/> the agent	<input type="checkbox"/> the common representative
---	--	------------------------------------	--

Name and Address

CHEN, Shizhong 7896 Camino Kiosco San Diego, CA 92122 United States of America	State of Nationality CN	State of Residence US
---	----------------------------	--------------------------

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

<input type="checkbox"/> the person	<input checked="" type="checkbox"/> the name	<input type="checkbox"/> the address	<input type="checkbox"/> the nationality	<input type="checkbox"/> the residence
-------------------------------------	--	--------------------------------------	--	--

Name and Address

CHEN, Shizhong	State of Nationality CN	State of Residence US
----------------	----------------------------	--------------------------

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Aino Metcalfe Telephone No.: (41-22) 338.83.38
---	---

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/09684

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 38/00, 45/05, 38/19, 39/395

US CL :514/2, 8, 12; 424/85.1,158.1, 145.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 8, 12; 424/85.1,158.1, 145.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, DIALOG, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/05309 A3 (THE ROCKEFELLER UNIVERSITY) 22 February 1996, (22-02-96), see the claims.	1-35
X, P	WO 96/35787 A1 (CHIRON CORPORATION) 14 November 1996 (14-11-96), see entire document, and claims.	1-35
X	PELLELYMOUNTER et al. Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice. Science, 28 July 1995, Vol. 269, see pages 540-543.	8-17, 18-26
X	HALAAS et al. Weight-Reducing Effects on the Plasma Protein Encoded by the obese Gene. Science, 28 July 1995, Vol. 269, see pages 543--547.	8-17, 18-26

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 SEPTEMBER 1997

Date of mailing of the international search report

23 SEP 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer
GARNETTE D. DRAPER

Telephone No. (703) 308-0196



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/09684

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GRUNFELD et al. Endotoxin and Cytokines Induce Expression of Leptin, the ob Gene Product, in Hamsters. Journal of Clinical Investigations. Clin. Invest. May 1996, Vol. 97, see pages 2152-2157.	1-35
X, P	SARRAF et al. Multiple Cytokines and Acute Inflammation Raise Mouse Leptin Levels: Potential Role in Inflammatory Anorexia. Journal of Experimental Medicine. 06 January 1997, Vol. 185, Number 1, see pages 171-175.	1-35
X, P	ROUBENOFF et al. TNF-alpha and leptin in adjuvant arthritis (AA): Implications for inflammatory cachexia. Arthritis & Rheumatism, September 1996, Vol. 39, No. 9 (supplement), see Abstract No. 302, page s77.	1-35
A, P	GAINSFORD et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc. Natl. Acad. Sci. December 1996, Vol. 93, see pages 14564-14568.	1-35
A, P	BENNETT et al. A role for leptin and its cognate receptor in hematopoiesis. Current Biology, 1996, Vol. 6, No. 9, see pages 1178-1180.	1-35

